USPTO issued Patent US12588856B2 to Biosense Webster (Israel) Ltd. on March 31, 2026. The patent protects a method for detecting progressively slowing cardiac activation by receiving cardiac signals sensed via electrodes, identifying signal components from activations, annotating those components, calculating time differences between annotations and corresponding activations, and identifying tissue locations demonstrating PSA. An EP map is presented with graphical indication of PSA locations. The filing date was December 14, 2022, and the application number is 18080875.

Organizations developing cardiac mapping, EP mapping systems, or related diagnostic technologies should conduct freedom-to-operate analyses to assess whether their products may fall within the scope of the 14 claims. R&D teams designing electrode-based cardiac signal processing systems should review the annotated signal identification and time-difference calculation methodology to evaluate potential design-around options. Patent counsel should be consulted for validity opinions or licensing inquiries.